Business Wire

The Melbourne Symphony Orchestra Selects Brightcove to Power New Digital Platform

Share

Brightcove Inc. (NASDAQ: BCOV), the global leader in video for business, today announced that the Melbourne Symphony Orchestra (MSO) is using Brightcove to power its new digital platform MSO.LIVE to cast the Orchestra’s 2021 season in Australia and around the world.

“Brightcove’s technology delivers a polished interface with exceptional quality of video and audio across multiple devices, to ensure we can deliver easily accessible, world-class digital experiences to all audiences,” said Sophie Galaise, Managing Director of the Melbourne Symphony Orchestra.

The MSO is a world-class orchestra with global credibility in providing enriching music experiences to audiences. MSO.LIVE offers 24-hour entertainment on-demand, live, and pre-recorded, delivering accessible and premium content as an alternative to traditional, in-person orchestral experiences. The MSO.LIVE experience is accessible, offering MSO concerts, family programming, and special events and performances from around the world.

A key driver for implementing Brightcove’s online video platform is to make performance experiences easily accessible and affordable to a wider audience, including those who are unable to attend in-person concerts.

The MSO’s main focus is to optimise its content delivery experience to retain existing orchestral music fans and attract new audiences from around the world to the MSO.LIVE platform. New performances are released monthly, and MSO.LIVE members are able to view content across devices and connected TVs.

Using Brightcove, MSO.LIVE demonstrates innovation within the Australian arts community by offering a contemporary content library personalised to audience preferences. “Among other criteria, we selected Brightcove as their local team of experts had the capabilities to integrate customer data with our CRM system,” said Ms. Galaise.

MSO.LIVE offers a range of traditional and contemporary content from both the MSO and other world-class orchestras from around the world, such as the Berliner Philharmoniker and Royal Concertgebouw Orchestra.

MSO.LIVE is priced at $15 per month or $144 per year for an annual subscription, or audiences can subscribe to a one-month pass or pay-per-view access. MSO.LIVE also offers a selection of free content, including programs for kids, audio, and more. View MSO.LIVE here.

“Our partnership with the Melbourne Symphony Orchestra demonstrates the power that video provides to the entertainment and music industry,” said Jennifer Smith, Chief Marketing Officer, Brightcove. “Brands in the Arts and Entertainment sector are embracing the hybrid model to allow them to grow their audiences to engage both in-person and online viewers. 2020 drove the urgency to pivot to new digital video experiences, and businesses are now embracing this as a long-term growth strategy. MSO.LIVE takes the orchestral experience to the next level and cements the MSO as a leader when it comes to the future of live performances,” said Smith.

As part of a longer-term strategy, the introduction of MSO.LIVE will help demonstrate Australia’s unique culture and celebrate the diverse talents of its local artists with the rest of the world.

About Melbourne Symphony Orchestra

Each year, the MSO engages with more than 5 million people through live concerts, TV, radio and online broadcasts, international and regional tours, recordings and education programs.

The MSO is a vital presence, both onstage and in the community, in cultivating classical music in Australia. Internationally acclaimed, the Orchestra nurtures strong cultural partnerships throughout South-East Asia. The MSO is the only Australian orchestra partnered with UNITEL, the world’s leading distributor of classical music programs for film, television and video.

The MSO regularly attracts great artists from around the globe, including Anne-Sophie Mutter, Lang Lang, Renée Fleming and Nick Cave, while bringing Melbourne’s finest musicians to the world through tours to China, Indonesia, Europe and the United States.

The nation’s first professional orchestra, the Melbourne Symphony Orchestra has been the sound of the city of Melbourne since 1906. www.mso.com.au.

About Brightcove Inc.

When video is done right, it can have a powerful and lasting effect. Hearts open. Minds change. Creativity thrives. Since 2004, Brightcove has been helping customers discover and experience the incredible power of video through its award-winning technology, empowering organisations in more than 70 countries across the globe to touch audiences in bold and innovative ways.

Brightcove achieves this by developing technologies once thought impossible, providing customer support without parallel or excuses, and leveraging the expertise and resources of a global infrastructure. Video is the world’s most compelling, exciting medium. Visit www.brightcove.com for more information. Video That Means Business™

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brightcove Press

Meredith Duhaime
Senior Public Relations Manager
Brightcove | (603) 785-8518
mduhaime@brightcove.com

Livia Budisetio
Account Executive
LEWIS Global Communications | (61) 411 208 431
brightcoveANZ@teamlewis.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 16:01:00 EET | Press release

Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ

Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 16:00:00 EET | Press release

Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as enterprises and AI developers alike seek a better, more predictable alternative to the hyperscalers.” Wasabi disrupted the cloud storage model in 2017 wi

Armis Secures Italy’s Primary Public Healthcare Provider for the City of Naples as Cyber Threats Increase13.1.2026 15:00:00 EET | Press release

Armis, the cyber exposure management & security company, today announced that ASL Napoli 1 Centro, Italy’s primary public healthcare provider for the City of Naples, is securing its attack surface using Armis Centrix™, the Armis Cyber Exposure Management Platform. Prior to working with Armis, ASL Napoli 1 Centro did not have the tools or capabilities to monitor physical and virtual assets in real time, which posed a challenge for its security and compliance. Armis Centrix™ was deployed with a clear goal: to provide ASL Napoli 1 Centro with a comprehensive, real-time view of its connected biomedical inventory and the associated risks to the overall environment. “Time-to-value was practically immediate; Armis began delivering valuable information as soon as the system was activated and connected to our internal network,” said Fulvio Paone, Director of the ICT and Digital Transformation Unit at ASL Napoli 1 Centro. “Armis has given us visibility into a critical area. This isn’t just about

Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge13.1.2026 15:00:00 EET | Press release

Opengear, a Digi International company (NASDAQ, DGII), today announced two new additions to its Network Resilience Platform: the CM8000 Series and the OM1300 Series. These next generation devices deliver compact, flexible, and automation-ready out-of-band infrastructure designed for a time when outages are increasing and distributed sites continue to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113807672/en/ Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge According to Opengear research, 84 percent of CIOs and CISOs have experienced a rise in outages over the past two years. The CM8000 Series and OM1300 Series were purpose-built to ensure that IT teams maintain access and control even when the production network is unavailable. The two series provide complementary approaches: CM8000 Series A serial-first recovery platform with integrated power control for core branches,

GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 15:00:00 EET | Press release

The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye